In a landmark collaboration, four of the world’s leading liver and oncology societies—the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD), the American Society of Clinical Oncology (ASCO), and the International Liver Cancer Association (ILCA)—have united to establish a comprehensive, globally harmonized framework for the design of clinical trials in hepatocellular carcinoma (HCC). This unprecedented joint effort transcends previous guidelines, which were typically developed by individual societies, to deliver an integrative, consensus-driven approach covering the entire spectrum of trial design, methodology, and outcome interpretation.
The significance of this new consensus lies in its broad scope, systematically addressing key aspects such as patient selection criteria, stratification parameters, primary and secondary endpoints, and the rigorous evaluation of clinical benefit across all HCC disease stages. By harmonizing these components, the document aims to reduce variability and fragmentation in trial design that have historically hampered the comparability and reproducibility of findings, thereby accelerating progress in HCC research and therapy development.
One of the defining features of this comprehensive guideline is its advocacy for the incorporation of patient-reported outcomes (PROs) and quality of life (QOL) assessments as integral endpoints in every phase of clinical trials. Recognizing that survival metrics alone do not fully capture the patient experience, the consensus encourages early and meaningful patient engagement starting from trial conception. This emphasis not only enriches the clinical relevance of study outcomes but also confronts disparities in access to trials, promoting equity and inclusivity in research participation.
From a methodological perspective, the consensus tackles the often challenging issue of non-proportional hazards (NPH) in survival analysis, a scenario that frequently arises in oncology trials where the risk of events varies over time. The document furnishes explicit guidance on selecting appropriate statistical models, including robust tools capable of handling NPH, alongside detailed recommendations for prespecified maturity thresholds and sensitivity analyses. These measures are designed to preserve the statistical validity of trial results while enhancing the clarity and clinical interpretability of data, even in complex analytic landscapes.
Moreover, the consensus introduces a structured approach for defining and quantifying the magnitude of clinical benefit. It proposes integrating validated surrogate endpoints alongside preliminary signals of overall survival (OS), thereby enabling accelerated regulatory approvals without compromising scientific rigor. This pragmatic strategy addresses the pressing clinical imperative to bring effective therapies to patients sooner, especially in scenarios where mature OS data would otherwise delay access to promising treatments.
To improve the robustness of clinical data, the document also delineates a core dataset of key variables that should be uniformly collected in phase II and III clinical trials. Standardizing data collection protocols is expected to enhance data quality, facilitate cross-study comparisons, and bolster reproducibility—elements critical for the coherent advancement of the HCC research field.
Despite these advances, the consensus poignantly highlights several urgent unresolved challenges that must be addressed to optimize HCC clinical research. Central among these is the development of predictive and prognostic biomarkers, which are essential for patient stratification, treatment personalization, and trial enrichment. The reliable validation of surrogate survival markers remains a priority, as does the design of clinical trials specifically tailored to populations that have been historically under-represented—most notably patients with Child–Pugh class B liver disease, a group with substantial unmet therapeutic needs.
The document also underscores the value of adopting innovative trial designs such as adaptive methodologies, which can dynamically modify trial parameters based on interim results. Such flexibility is poised to accelerate biomarker validation and streamline the clinical translation of novel agents, potentially transforming the pace and precision of HCC drug development.
An additional important consideration put forth by the consensus is the universal requirement for tumor biopsy prior to patient enrollment in all HCC clinical trials, a recommendation endorsed to deepen the molecular understanding of tumors and support biomarker-driven investigations. This step promises to refine therapeutic targeting and enhance the scientific yield of clinical studies.
Early and intermediate stages of HCC treatment are identified as areas ripe for randomized controlled trials (RCTs) exploring the integration of systemic agents with curative-intent interventions such as resection or ablation. Trials investigating neoadjuvant strategies and adjuvant systemic therapies before transplantation, as well as comparisons between locoregional treatments alone versus combination approaches, are particularly emphasized to optimize patient outcomes.
In advanced-stage disease, the consensus calls for rigorously designed RCTs to define optimal control arms, especially in the context of second-line systemic therapies and in patients with compromised liver function (Child–Pugh B). It advocates for the systematic inclusion of patients with adverse prognostic features, such as main portal vein thrombosis, an approach aimed at broadening the applicability of trial findings and facilitating therapeutic advances for high-risk cohorts.
Robust inclusion of exploratory biomarker analyses in trials is championed as a standard practice to unravel mechanistic insights and guide precision oncology strategies. Complementary to this, efforts to enhance preclinical drug testing methodologies are recognized as critical to improving the translational pipeline from bench to bedside.
Intertwined throughout the guidance is the priority to incorporate patient-reported outcomes systematically, ensuring that trial endpoints reflect not only survival but also the lived experiences of patients navigating HCC therapy. This alignment aligns clinical research with the evolving paradigm of patient-centered care, where treatment benefits are measured across multiple dimensions of health and well-being.
This unparalleled collaboration among EASL, AASLD, ASCO, and ILCA marks a transformative milestone in HCC clinical research. By unifying standards and reinforcing methodological rigor, the consensus paves the way for equitable global progress in disease understanding, therapeutic innovation, and patient care. It equips researchers, clinicians, regulators, and industry stakeholders with a robust blueprint to navigate the complexities of HCC trials, ultimately accelerating the discovery and delivery of life-extending treatments for one of the world’s most challenging cancers.
As the oncology community embraces this harmonized framework, the expectation is that future HCC trials will be characterized by improved design consistency, enhanced data quality, and meaningful patient engagement. Collectively, these advances are anticipated to foster scientific breakthroughs and deliver new hope to patients burdened by hepatocellular carcinoma worldwide.
Subject of Research: Clinical trial design and end points in hepatocellular carcinoma (HCC)
Article Title: Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement
Article References:
Llovet, J.M., Mauro, E., Rimassa, L. et al. Trial design and end points in hepatocellular carcinoma: an EASL–AASLD–ILCA consensus statement. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01160-z
Image Credits: AI Generated
